跳至主要内容
临床试验/NCT01340885
NCT01340885已完成4 期

Cognitive Dysfunction in PD: Pathophysiology and Potential Treatments, a Pilot Study

Oregon Health and Science University1 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2011年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
9
试验地点
1
主要终点
Attention Network Effects

研究概览

简要总结

The purpose of this study is to determine the relationship between attention and quality of life and how rivastigmine and atomoxetine alter attention in non-demented persons with Parkinson's disease (PD).

详细描述

Cognitive dysfunction can occur in early stage of Parkinson's disease (PD) and increases as PD progresses. Attention deficits in PD patients with dementia strongly predict the impairment of their daily living activities.

Previous studies have shown that atomoxetine improves PD executive dysfunction and rivastigmine improves attention deficits in PD patients with dementia without worsening the motor symptoms.

The aim of this study is to examine the effect of atomoxetine and rivastigmine on attention and quality of life in PD patients without disabling cognitive impairment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinical diagnosis of Parkinson's disease
  • Respond to levodopa therapy

排除标准

  • Psychiatric disorders including anxiety disorders, dissociative disorders, mood disorders, schizophrenia and related disorders, or ADD/ADHD
  • Any clinically unstable disease such as cancer, HIV/AIDS, heart condition, liver disease, kidney or renal failure or others that might require hospitalization
  • Evidence for another neurological disease (history of seizures, Alzheimer disease, multiple sclerosis or other movement disorders);
  • Currently using any of the study drugs;
  • Colorblindness

研究组 & 干预措施

Placebo

Placebo Comparator

sugar pill

干预措施: Placebo (Other)

atomoxetine

Active Comparator

Strattera 10-30 mg b.i.d.

干预措施: Strattera (Drug)

rivastigimine

Active Comparator

Exelon 1.5-4.5 mg b.i.d.

干预措施: Exelon (Drug)

结局指标

主要结局

Attention Network Effects

时间窗: 6 weeks

次要结局

  • Depression(6 weeks)
  • Daytime Sleepiness(6 weeks)
  • Quality of Life(6 weeks)
  • Fatigue(6 weeks)
  • Stroop Color Word Test(6 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jau-Shin Lou

Associate Professor

Oregon Health and Science University

研究点 (1)

Loading locations...

相似试验